HRP20221459T1 - Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe - Google Patents
Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe Download PDFInfo
- Publication number
- HRP20221459T1 HRP20221459T1 HRP20221459TT HRP20221459T HRP20221459T1 HR P20221459 T1 HRP20221459 T1 HR P20221459T1 HR P20221459T T HRP20221459T T HR P20221459TT HR P20221459 T HRP20221459 T HR P20221459T HR P20221459 T1 HRP20221459 T1 HR P20221459T1
- Authority
- HR
- Croatia
- Prior art keywords
- human
- gene
- gene segments
- segments
- genetically modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594944P | 2017-12-05 | 2017-12-05 | |
| US201762594946P | 2017-12-05 | 2017-12-05 | |
| US201762609241P | 2017-12-21 | 2017-12-21 | |
| US201762609251P | 2017-12-21 | 2017-12-21 | |
| EP18821945.5A EP3720279B1 (en) | 2017-12-05 | 2018-12-04 | Mice having an engineered immunoglobulin lambda light chain and uses thereof |
| PCT/US2018/063841 WO2019113065A1 (en) | 2017-12-05 | 2018-12-04 | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221459T1 true HRP20221459T1 (hr) | 2023-01-20 |
Family
ID=64734263
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250920TT HRP20250920T1 (hr) | 2017-12-05 | 2018-12-04 | Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe |
| HRP20221459TT HRP20221459T1 (hr) | 2017-12-05 | 2018-12-04 | Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250920TT HRP20250920T1 (hr) | 2017-12-05 | 2018-12-04 | Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11051498B2 (enExample) |
| EP (3) | EP3720279B1 (enExample) |
| JP (2) | JP7430636B2 (enExample) |
| KR (2) | KR20250022220A (enExample) |
| CN (2) | CN116058333A (enExample) |
| AU (2) | AU2018381316B2 (enExample) |
| BR (1) | BR112020011184A2 (enExample) |
| CA (1) | CA3084049A1 (enExample) |
| DK (2) | DK4140297T3 (enExample) |
| ES (2) | ES2928995T3 (enExample) |
| FI (1) | FI4140297T3 (enExample) |
| HR (2) | HRP20250920T1 (enExample) |
| HU (2) | HUE071852T2 (enExample) |
| IL (2) | IL274797B2 (enExample) |
| LT (2) | LT3720279T (enExample) |
| MX (2) | MX2020005830A (enExample) |
| PL (2) | PL4140297T3 (enExample) |
| PT (2) | PT4140297T (enExample) |
| RS (2) | RS63772B1 (enExample) |
| SG (1) | SG11202003044SA (enExample) |
| SI (2) | SI4140297T1 (enExample) |
| SM (2) | SMT202500277T1 (enExample) |
| TW (2) | TW202438676A (enExample) |
| WO (1) | WO2019113065A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| RU2580017C2 (ru) | 2010-07-26 | 2016-04-10 | Трианни, Инк. | Трансгенные животные и способы применения |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| EP3720279B1 (en) | 2017-12-05 | 2022-09-21 | Regeneron Pharmaceuticals, Inc. | Mice having an engineered immunoglobulin lambda light chain and uses thereof |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| BR112021016173A2 (pt) | 2019-02-22 | 2021-11-03 | Regeneron Pharma | Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma |
| KR20220025838A (ko) * | 2019-07-01 | 2022-03-03 | 트리아니, 인코포레이티드 | 유전자이식 포유동물 및 사용 방법 |
| ES3027509T3 (en) * | 2019-07-01 | 2025-06-16 | Zoetis Services Llc | Transgenic rodents and methods of use thereof |
| KR20230066386A (ko) | 2020-09-11 | 2023-05-15 | 리제너론 파마슈티칼스 인코포레이티드 | 항원 특이적 항체의 확인 및 제조 |
| CA3199879A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| US12371487B2 (en) | 2020-12-23 | 2025-07-29 | Regeneron Pharmaceuticals, Inc. | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same |
| CN114763558B (zh) * | 2021-01-14 | 2024-02-20 | 上海泰槿生物技术有限公司 | 重组基因组、非人哺乳动物细胞及其产生方法和用途 |
| CN118511853A (zh) * | 2021-03-31 | 2024-08-20 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| ES2301183T3 (es) * | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| CA2422155A1 (en) * | 2000-08-03 | 2002-02-14 | Wim Van Schooten | Production of humanized antibodies in transgenic animals |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP3269235B1 (en) | 2001-11-30 | 2022-01-26 | Amgen Fremont Inc. | Transgenic mice bearing human ig lambda light chain genes |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| NZ583799A (en) * | 2007-09-12 | 2011-12-22 | Probiodrug Ag | Transgenic mice comprising a DNA transgene encoding ABeta peptide |
| PL3456190T3 (pl) * | 2008-06-27 | 2022-06-06 | Merus N.V. | Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy |
| LT2346994T (lt) | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
| EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| US9445581B2 (en) * | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| RU2425880C2 (ru) | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| CN104404050B (zh) | 2010-06-22 | 2018-06-08 | 瑞泽恩制药公司 | 杂交轻链小鼠 |
| HUE047687T2 (hu) | 2011-02-25 | 2020-05-28 | Regeneron Pharma | ADAM6 egér |
| KR102762747B1 (ko) | 2011-10-17 | 2025-02-05 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 마우스 |
| US9253965B2 (en) * | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US9706759B2 (en) * | 2011-12-20 | 2017-07-18 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
| EP3912465A1 (en) | 2012-02-01 | 2021-11-24 | Regeneron Pharmaceuticals, Inc. | Humanized rodents that express heavy chains containing vl domains |
| KR102266274B1 (ko) * | 2012-06-12 | 2021-06-17 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물 |
| EP3561050B1 (en) | 2013-02-20 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| MX369747B (es) | 2013-04-16 | 2019-11-20 | Regeneron Pharma | Modificación dirigida del genoma de rata. |
| AU2014330922A1 (en) | 2013-10-01 | 2016-03-03 | Kymab Limited | Animal models and therapeutic molecules |
| DK3354732T3 (da) | 2014-06-23 | 2020-04-06 | Regeneron Pharma | Nukleasemedieret dna-samling |
| RU2734770C2 (ru) | 2014-11-21 | 2020-10-23 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк |
| RU2707137C2 (ru) | 2014-12-19 | 2019-11-22 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания |
| KR102784608B1 (ko) | 2016-06-03 | 2025-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
| GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
| EP3720279B1 (en) | 2017-12-05 | 2022-09-21 | Regeneron Pharmaceuticals, Inc. | Mice having an engineered immunoglobulin lambda light chain and uses thereof |
-
2018
- 2018-12-04 EP EP18821945.5A patent/EP3720279B1/en active Active
- 2018-12-04 HU HUE22188627A patent/HUE071852T2/hu unknown
- 2018-12-04 WO PCT/US2018/063841 patent/WO2019113065A1/en not_active Ceased
- 2018-12-04 SG SG11202003044SA patent/SG11202003044SA/en unknown
- 2018-12-04 ES ES18821945T patent/ES2928995T3/es active Active
- 2018-12-04 PL PL22188627.8T patent/PL4140297T3/pl unknown
- 2018-12-04 SI SI201831243T patent/SI4140297T1/sl unknown
- 2018-12-04 CN CN202211211765.0A patent/CN116058333A/zh active Pending
- 2018-12-04 SI SI201830769T patent/SI3720279T1/sl unknown
- 2018-12-04 US US16/209,820 patent/US11051498B2/en active Active
- 2018-12-04 RS RS20221094A patent/RS63772B1/sr unknown
- 2018-12-04 LT LTEPPCT/US2018/063841T patent/LT3720279T/lt unknown
- 2018-12-04 AU AU2018381316A patent/AU2018381316B2/en active Active
- 2018-12-04 RS RS20250752A patent/RS67058B1/sr unknown
- 2018-12-04 PT PT221886278T patent/PT4140297T/pt unknown
- 2018-12-04 SM SM20250277T patent/SMT202500277T1/it unknown
- 2018-12-04 ES ES22188627T patent/ES3035461T3/es active Active
- 2018-12-04 CA CA3084049A patent/CA3084049A1/en active Pending
- 2018-12-04 CN CN201880078631.1A patent/CN111432635B/zh active Active
- 2018-12-04 US US16/769,821 patent/US20210345591A1/en not_active Abandoned
- 2018-12-04 KR KR1020257002291A patent/KR20250022220A/ko active Pending
- 2018-12-04 PL PL18821945.5T patent/PL3720279T3/pl unknown
- 2018-12-04 EP EP22188627.8A patent/EP4140297B1/en active Active
- 2018-12-04 TW TW112148224A patent/TW202438676A/zh unknown
- 2018-12-04 MX MX2020005830A patent/MX2020005830A/es unknown
- 2018-12-04 BR BR112020011184-8A patent/BR112020011184A2/pt unknown
- 2018-12-04 LT LTEP22188627.8T patent/LT4140297T/lt unknown
- 2018-12-04 SM SM20220448T patent/SMT202200448T1/it unknown
- 2018-12-04 IL IL274797A patent/IL274797B2/en unknown
- 2018-12-04 IL IL318197A patent/IL318197A/en unknown
- 2018-12-04 HR HRP20250920TT patent/HRP20250920T1/hr unknown
- 2018-12-04 DK DK22188627.8T patent/DK4140297T3/da active
- 2018-12-04 HR HRP20221459TT patent/HRP20221459T1/hr unknown
- 2018-12-04 KR KR1020207016646A patent/KR102760506B1/ko active Active
- 2018-12-04 PT PT188219455T patent/PT3720279T/pt unknown
- 2018-12-04 TW TW107143491A patent/TWI827567B/zh active
- 2018-12-04 HU HUE18821945A patent/HUE060608T2/hu unknown
- 2018-12-04 JP JP2020530565A patent/JP7430636B2/ja active Active
- 2018-12-04 DK DK18821945.5T patent/DK3720279T3/da active
- 2018-12-04 EP EP25169830.4A patent/EP4596688A3/en active Pending
- 2018-12-04 FI FIEP22188627.8T patent/FI4140297T3/fi active
-
2020
- 2020-07-13 MX MX2024004496A patent/MX2024004496A/es unknown
-
2021
- 2021-06-01 US US17/335,727 patent/US12356967B2/en active Active
-
2024
- 2024-01-31 JP JP2024012752A patent/JP7765514B2/ja active Active
-
2025
- 2025-06-18 AU AU2025204547A patent/AU2025204547A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221459T1 (hr) | Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe | |
| HRP20220253T1 (hr) | Miševi s ograničenim teškim lancem imunoglobulina | |
| HRP20191191T1 (hr) | Miš sa zajedničkim lakim lancem | |
| NZ730271A (en) | Non-human animals expressing ph-sensitive immunoglobulin sequences | |
| NZ743520A (en) | Humanized universal light chain mice | |
| JP5756802B2 (ja) | 最小cdrを有する抗体を産生するトランスジェニック動物 | |
| AU2024200582A1 (en) | Non-human animals having an engineered immunoglobulin lambda light chain locus | |
| CA2865644A1 (en) | Mice that produce antigen-binding proteins with ph-dependent binding characteristics | |
| IL305557B1 (en) | Non-human animals capable of engineered dh-dh rearrangement and uses thereof | |
| NZ763183B2 (en) | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof | |
| NZ763183A (en) | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof | |
| US12428471B2 (en) | Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion | |
| US20250388651A1 (en) | Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion | |
| US12102070B2 (en) | Camelization of a human variable domain by gene conversion | |
| AU2019284252B2 (en) | Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion | |
| AU2025271118A1 (en) | Transgenic chicken that makes antibodies with long CDR-H3s stabilized by multiple disulfide bridges and diversified by gene conversion | |
| MC et al. | Novato, CA 94949 (US) |